Knockdown of HNRNPA1 inhibits lung adenocarcinoma cell proliferation through cell cycle arrest at G0/G1 phase

Gene

Volumn 576, Issue 2, 2016, Pages 791-797

  Liu, Xianxun ^a   Zhou, Yan ^a   Lou, Yuqing ^a   Zhong, Hua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cell cycle arrest; Cell proliferation; HNRNPA1; Lung cancer; RNA interference

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; HNRNP A1; SMALL INTERFERING RNA;

A-549 CELL LINE; ADULT; ARTICLE; CANCER PATIENT; CANCER TISSUE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; ADENOCARCINOMA; AGED; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEK293 CELL LINE; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

ADENOCARCINOMA; AGED; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RNA, SMALL INTERFERING; TUMOR STEM CELL ASSAY;

EID: 84973434925     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.11.009     Document Type: Article

References (33)

1. Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., et al. EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. Int. J. Med. Sci. 10:3 (2013), 320–330, 10.7150/ijms.4609.
2. Brown, M., Cohen, J., Arun, P., Chen, Z., Van Waes, C., NF-kappaB in carcinoma therapy and prevention. Expert Opin. Ther. Targets 12:9 (2008), 1109–1122, 10.1517/14728222.12.9.1109.
3. de Lange, T., Jacks, T., For better or worse? Telomerase inhibition and cancer. Cell 98:3 (1999), 273–275.
4. DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D., Kramer, J.L., et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 64:4 (2014), 252–271, 10.3322/caac.21235.
5. Feng, J., Funk, W.D., Wang, S.S., Weinrich, S.L., Avilion, A.A., Chiu, C.P., et al. The RNA component of human telomerase. Science (New York, NY) 269:5228 (1995), 1236–1241.
6. Fiset, S., Chabot, B., HnRNP A1 may interact simultaneously with telomeric DNA and the human telomerase RNA in vitro. Nucleic Acids Res. 29:11 (2001), 2268–2275.
7. Gu, J., Li, K., Li, M., Wu, X., Zhang, L., Ding, Q., et al. A role for p21-activated kinase 7 in the development of gastric cancer. FEBS J. 280:1 (2013), 46–55, 10.1111/febs.12048.
8. Hahn, W.C., Stewart, S.A., Brooks, M.W., York, S.G., Eaton, E., Kurachi, A., et al. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5:10 (1999), 1164–1170, 10.1038/13495.
9. Harley, C.B., Kim, N.W., Prowse, K.R., Weinrich, S.L., Hirsch, K.S., West, M.D., et al. Telomerase, cell immortality, and cancer. Cold Spring Harb. Symp. Quant. Biol. 59 (1994), 307–315.
10. Hayden, M.S., Ghosh, S., Shared principles in NF-kappaB signaling. Cell 132:3 (2008), 344–362, 10.1016/j.cell.2008.01.020.
11. Herbert, B., Pitts, A.E., Baker, S.I., Hamilton, S.E., Wright, W.E., Shay, J.W., et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. U. S. A. 96:25 (1999), 14276–14281.
12. Iervolino, A., Santilli, G., Trotta, R., Guerzoni, C., Cesi, V., Bergamaschi, A., et al. HnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol. Cell. Biol. 22:7 (2002), 2255–2266.
13. Inoue, J., Gohda, J., Akiyama, T., Semba, K., NF-kappaB activation in development and progression of cancer. Cancer Sci. 98:3 (2007), 268–274, 10.1111/j.1349-7006.2007.00389.x.
14. Izaurralde, E., Jarmolowski, A., Beisel, C., Mattaj, I.W., Dreyfuss, G., Fischer, U., A role for the M9 transport signal of hnRNP A1 in mRNA nuclear export. J. Cell Biol. 137:1 (1997), 27–35.
15. Karlseder, J., Smogorzewska, A., de Lange, T., Senescence induced by altered telomere state, not telomere loss. Science (New York, NY) 295:5564 (2002), 2446–2449, 10.1126/science.1069523.
16. Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science (New York, NY). 266:5193 (1994), 2011–2015.
17. LaBranche, H., Dupuis, S., Ben-David, Y., Bani, M.R., Wellinger, R.J., Chabot, B., Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase. Nat. Genet. 19:2 (1998), 199–202, 10.1038/575.
18. Li, H., Lin, X., Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine 41:1 (2008), 1–8, 10.1016/j.cyto.2007.09.016.
19. Li, S., Xu, H., Ding, H., Huang, Y., Cao, X., Yang, G., et al. Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J. Pathol. 218:3 (2009), 327–336, 10.1002/path.2543.
20. Luqman, S., Pezzuto, J.M., NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother. Res. 24:7 (2010), 949–963, 10.1002/ptr.3171.
21. Ma, Y.L., Peng, J.Y., Zhang, P., Huang, L., Liu, W.J., Shen, T.Y., et al. Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J. Proteome Res. 8:10 (2009), 4525–4535, 10.1021/pr900365e.
22. Melisi, D., Chiao, P.J., NF-kappa B as a target for cancer therapy. Expert Opin. Ther. Targets 11:2 (2007), 133–144, 10.1517/14728222.11.2.133.
23. Mok, T., Yang, J.J., Lam, K.C., Treating patients with EGFR-sensitizing mutations: first line or second line–is there a difference?. J. Clin. Oncol. 31:8 (2013), 1081–1088, 10.1200/jco.2012.43.0652.
24. Pao, W., Girard, N., New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:2 (2011), 175–180, 10.1016/s1470-2045(10)70087-5.
25. Patry, C., Bouchard, L., Labrecque, P., Gendron, D., Lemieux, B., Toutant, J., et al. Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res. 63:22 (2003), 7679–7688.
26. Romero-Garcia, S., Prado-Garcia, H., Lopez-Gonzalez, J.S., Transcriptional analysis of hnRNPA0, A1, A2, B1, and A3 in lung cancer cell lines in response to acidosis, hypoxia, and serum deprivation conditions. Exp. Lung Res. 40:1 (2014), 12–21, 10.3109/01902148.2013.856049.
27. Sahu, I., Sangith, N., Ramteke, M., Gadre, R., Venkatraman, P., A novel role for the proteasomal chaperone PSMD9 and hnRNPA1 in enhancing IkappaBalpha degradation and NF-kappaB activation - functional relevance of predicted PDZ domain-motif interaction. FEBS J. 281:11 (2014), 2688–2709, 10.1111/febs.12814.
28. Siegel, R., Ma, J.M., Zou, Z.H., Jemal, A., Cancer statistics, 2014. CA Cancer J. Clin. 64:1 (2014), 9–29, 10.3322/caac.21208.
29. Tucker, Z.C., Laguna, B.A., Moon, E., Singhal, S., Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat. Rev. 38:6 (2012), 650–661, 10.1016/j.ctrv.2011.11.008.
30. Xu, X., Joh, H.D., Pin, S., Schiller, N.I., Prange, C., Burger, P.C., et al. Expression of multiple larger-sized transcripts for several genes in oligodendrogliomas: potential markers for glioma subtype. Cancer Lett. 171:1 (2001), 67–77.
31. Yamamoto, H., Toyooka, S., Mitsudomi, T., Impact of EGFR mutation analysis in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 63:3 (2009), 315–321, 10.1016/j.lungcan.2008.06.021.
32. Zarogoulidis, K., Zarogoulidis, P., Darwiche, K., Boutsikou, E., Machairiotis, N., Tsakiridis, K., et al. Treatment of non-small cell lung cancer (NSCLC). J. Thorac. Dis. 5:Suppl. 4 (2013), S389–S396, 10.3978/j.issn.2072-1439.2013.07.10.
33. Zhou, Z.J., Dai, Z., Zhou, S.L., Fu, X.T., Zhao, Y.M., Shi, Y.H., et al. Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. Int. J. Cancer (Trans.) Journal international du cancer, 132(5), 2013, 1080–1089, 10.1002/ijc.27742.